Gastrodin Inhibits Expression of Inducible NO Synthase, Cyclooxygenase-2 and Proinflammatory Cytokines in Cultured LPS-Stimulated Microglia via MAPK Pathways

Ji-Nan Dai1,*, Yi Zong1,*, Lian-Mei Zhong2, Yue-Min Li1, Wei Zhang2, Li-Gong Bian1, Qing-Long Ai2, Yi-Dan Liu3, Jun Sun1,*, Di Lu1,*,4*

1 Department of Anatomy, Kunming Medical University, Kunming, Yunnan, China, 2 Department of Neurology, the First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China, 3 Kunming Pharmaceutical Corporation, Kunming, Yunnan, China, 4 Rehabilitation Engineering Research Laboratory, Biomedicine Engineering Research Centre, Kunming Medical University, Kunming, Yunnan, China

Abstract

Background: Microglial activation plays an important role in neurodegenerative diseases by producing several proinflammatory enzymes and proinflammatory cytokines. The phenolic glucoside gastrodin, a main constituent of a Chinese herbal medicine, has been known to display anti-inflammatory properties. The current study investigates the potential mechanisms whereby gastrodin affects the expression of potentially pro-inflammatory proteins by cultured murine microglial BV-2 cells stimulated with lipopolysaccharide (LPS).

Methodology/Principal Findings: BV-2 cells were pretreated with gastrodin (30, 40, and 60 μM) for 1 h and then stimulated with LPS (1 μg/ml) for another 4 h. The effects on proinflammatory enzymes, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and proinflammatory cytokines, tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β), are analysed by double-immunofluorescence labeling and RT-PCR assay. To reveal the mechanisms of action of gastrodin we investigated the involvement of mitogen-activated protein kinases (MAPKs) cascades and their downstream transcription factors, nuclear factor-kB (NF-kB) and cyclic AMP-responsive element (CRE)-binding protein (CREB). Gastrodin significantly reduced the LPS-induced protein and mRNA expression levels of iNOS, COX-2, TNF-α, IL-1β and NF-kB. LPS (1 μg/ml, 30 min)-induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), c-Jun N-terminal protein kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK) and this was inhibited by pretreatment of BV-2 cells with different concentrations of gastrodin (30, 40, and 60 μM). In addition, gastrodin blocked LPS-induced phosphorylation of inhibitor kB-α (IkB-α) (and hence the activation of NF-kB) and of CREB, respectively.

Conclusion and Implications: This study indicates that gastrodin significantly attenuates levels of neurotoxic proinflammatory mediators and proinflammatory cytokines by inhibition of the NF-kB signaling pathway and phosphorylation of MAPKs in LPS-stimulated microglial cells. Arising from the above, we suggest that gastrodin has a potential as an anti-inflammatory drug candidate in neurodegenerative diseases.

Citation: Dai J-N, Zong Y, Zhong L-M, Li Y-M, Zhang W, et al. (2011) Gastrodin Inhibits Expression of Inducible NO Synthase, Cyclooxygenase-2 and Proinflammatory Cytokines in Cultured LPS-Stimulated Microglia via MAPK Pathways. PLoS ONE 6(7): e21891. doi:10.1371/journal.pone.0021891

Editor: Joao B. Calixto, Universidad Federal de Santa Catarina, Brazil

Received March 29, 2011; Accepted June 8, 2011; Published July 12, 2011

Copyright: © 2011 Dai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part by grants (30860336 and 30560170) from the National Natural Sciences Foundation of China, the grants (2008CC007 and 2009CC033) from the Department of Science and Technology of Yunnan Province, and the grants (2008CD016 and 2010CD156) from the Joint Special Funds for the Department of Science and Technology of Yunnan Province-Kunming Medical University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.

Competing Interests: One of the authors, Y. D. Liu, is employed by a commercial company, Kunming Pharmaceutical Corporation. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: sunjun91@hotmail.com (JS); ludi20040609@126.com (DL)
† These authors contributed equally to this work.

Introduction

Microglial cells are the resident macrophage-like population of cells, which has been proposed to play a pivotal role in the innate immune response in the central nervous system (CNS) [1]. Although activated microglia scavenge dead cells from the CNS and secrete different neurotrophic factors for neuronal survival [2,3,4], it is believed that severe activation causes various autoimmune responses leading to neuronal death and brain injury [5,6]. Activation of microglia has been implicated in the pathogenesis of variety of neurodegenerative diseases, including multiple sclerosis, Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease [7,8,9]. Activation of microglia and consequent release of proinflammatory and/or cytotoxic factors such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), nitric oxide (NO), reactive oxygen species (ROS), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) are believed to contribute to neurodegenerative processes [10,11,12,13].

iNOS is not normally expressed in the brain, but inflammatory stimuli such as lipopolysaccharide (LPS) and cytokines cause its
expression in microglia and astrocytes [14]. Once expressed, iNOS produces high levels of NO continuously [15]. A number of studies have shown that the iNOS along with the release of NO by activated microglia contributes to progress neurodegeneration and aggravate neuronal diseases [16]. NO activates COX-2 resulting in the increased release of proinflammatory prostaglandins [17]. Induction of COX-2 expression and enzymatic activity can be associated with the management of inflammation and several neuronal diseases [18].

It has recently been suggested that the activation of microglia can increase neurotoxicity through the production of proinflammatory and cytotoxic factors in neuron-glia cultures treated with LPS, β-amyloid, glutamate, and arachidonate [19]. One of these widely used stimuli is LPS, a bacterial endotoxin used to study experimentally induced infection, inflammation, or tissue damage, as well as the biochemistry of inflammatory responses. LPS activates nuclear factor-κB (NF-κB), cyclic AMP responsive element-binding protein (CREB) and mitogen-activated protein kinases (MAPKs) family, which are classified into at least three components: extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinase (JNK), and p38 MAPK [20], which have been implicated in the release of immune-related cytotoxic factors such as iNOS, COX-2, and proinflammatory cytokines [12,21].

The phenolic glucoside gastrodin (Figure 1), the main active ingredient of an ancient Chinese herb Tianma (Gastrodia elata Bl.), is considered to have several beneficial properties. Gastrodin has been suggested to be effective as an antioxidant, analgesic, and sedative effective against vertigo, general paralysis, epilepsy, and tetanus [22]. Gastrodin could penetrate through the blood-brain barrier into brain, and it was rapidly decomposed to β-hydroxybenzyl alcohol (HBA) in brain, liver, and blood [23]. It is well known that gastrodin ameliorates cerebral damage after transient focal cerebral ischemia by promoting the ability to reduce ROS damage in vivo and hippocampal neuronal death and excitotoxicity in vitro [24] and has a neuroprotective action against hypoxia in the cultured cortical neuron [25]. There are numerous reports in the literature show that gastrodin and HBA, an aglycone of gastrodin, may improve learning and facilitate memory consolidation and retrieval [26,27]. There is, however, no report on the bioactive principles and the detailed mechanisms responsible for the anti-inflammatory activity of this herbal plant.

In the present study, we attempted to elucidate the anti-inflammatory potential of gastrodin by investigating the effect of gastrodin on the inflammatory response induced by LPS in murine microglial BV-2 cells. To further investigate the underlying mechanisms, the involvement of CREB, NF-κB and MAPKs was also examined. The present study provides information revealing gastrodin as a potential candidate compound with anti-inflammatory actions and suggests a scientific basis for further investigation of gastrodin against neuroinflammatory conditions.

Figure 1. Structure of gastrodin.

doi:10.1371/journal.pone.0021891.g001

Results

Gastrodin inhibits LPS-stimulated expression of iNOS and COX-2 proteins and mRNA in BV-2 cells

To investigate the effect of gastrodin on LPS-stimulated microglial activation, BV-2 cells were stimulated with LPS (1 μg/ml) which resulted in increase of the protein and mRNA levels of iNOS (Figure 2). Pre-treatment with gastrodin (30, 40, and 60 μM) notably inhibited dose-dependently iNOS protein and mRNA levels (Figure 2), compared with LPS-treated control.

Effect of gastrodin on another proinflammatory enzyme, COX-2 was examined by double-immunofluorescence labeling and RT-PCR assay. Stimulation of BV-2 cells with LPS led to increased expression of protein and mRNA for COX-2 (Figure 3). Gastrodin dose-dependently decreased the increased expression of COX-2 protein and mRNA stimulated by LPS (Figure 3).

Gastrodin attenuates LPS-stimulated the production of the proinflammatory cytokines TNF-α and IL-1β at the transcriptional and translational levels in BV-2 cells

To investigate whether gastrodin represses the production of these proinflammatory cytokines, which play central roles in inflammatory disease, BV-2 cells were stimulated with LPS (1 μg/ml) in the presence or absence of gastrodin (30, 40, and 60 μM). After treatment with LPS, the protein levels of the cytokines in BV-2 cells were measured. The protein levels of TNF-α and IL-1β increased in LPS-stimulated BV-2 cells. Pre-treatment with gastrodin resulted in a significant decrease in cytokine production (Figure 4A and 5A).

To further investigate whether the inhibitory effect of gastrodin on TNF-α and IL-1β production is due to the reduced expression of cognate genes, the effect of gastrodin on mRNA expression of TNF-α and IL-1β was assessed in LPS-stimulated BV-2 cells. As shown in Figure 4B and 5B, the mRNA expression of these inflammatory mediators was very low or hardly detectable in unstimulated BV-2 cells. However, BV-2 cells expressed high levels of TNF-α and IL-1β mRNA when stimulated with LPS (1 μg/ml). Furthermore, gastrodin suppressed LPS-induced expression of these genes in a concentration-dependent manner. In contrast, the level of β-actin mRNA was not affected by LPS and gastrodin treatment (Figure 4B and 5B).

Gastrodin suppresses LPS-induced expression of NF-κB/RelA protein, phosphorylation of IκB-α and CREB in BV-2 cells

To further elucidate the mechanisms of gastrodin on the inhibition of expression of iNOS, COX-2, and proinflammatory cytokines in microglia, the study examined the effect of gastrodin on NF-κB and CREB, two major transcription factors involved in the expression of these inflammatory mediators. The processes of NF-κB activation include IκB-α degradation through phosphorylation and a subsequent nuclear translocation of NF-κB. We determined whether the inhibitory effects of gastrodin occurred through the blockade of NF-κB activation in BV-2 cells. LPS induced expression of NF-κB/RelA protein and mRNA within 4 h after stimulation, which was inhibited by gastrodin (Figure 6). Meanwhile, as shown in Figure 7A, pre-treatment of gastrodin (30, 40, and 60 μM) suppressed the LPS induced phosphorylation of IκB-α.

CREB is the physiological substrate for MAPKs and stress-activated protein kinases-1 (MSK1), which is activated by ERK and p38 MAPK-mediated signaling in response to LPS. CREB activation was markedly stimulated by LPS, and this activation
was significantly inhibited by pre-treatment with gastrodin, at all three concentrations (Figure 7B).

Gastrodin decreases LPS-induced phosphorylation of MAPKs family in BV-2 cells

The effect of gastrodin on MAPKs, which are upstream signaling molecules in inflammatory reactions, was examined in the LPS-stimulated BV-2 cells. Western blot analysis was carried out using the phospho- or total forms of antibodies against the three MAPKs, ERK1/2, JNK, and p38 MAPK. It was observed that gastrodin (30, 40, and 60 μM) remarkably decreased the LPS-stimulated phosphorylation of ERK1/2 at 30 min, respectively, whereas it had no effect on the expression level of ERK1/2 in LPS-stimulated BV-2 cells. (Figure 7C). Meanwhile, gastrodin at all concentrations used significantly suppressed the phosphorylation of JNK and p38 MAPK, respectively, but did not affect the expression level of β-actin, even at 60 μM (Figure 7C).

Figure 2. Inhibitory effects of gastrodin on the LPS-induced expression of protein and mRNA for iNOS in BV-2 cells. Approximately $1 \times 10^6$ cells/ml were seeded in six-well plates and incubated until 80% confluency. Cells were pre-treated with gastrodin (30, 40, and 60 μM) for 1 h, then exposed to 1 μg/ml LPS for 4 h. The levels of protein and the corresponding mRNA were determined by double-immunofluorescence labeling and RT-PCR as described in the Methods. Panel A shows the immunofluorescence images for protein expression of iNOS and Panel B shows the corresponding mRNA data. The relative mRNA level was quantified by scanning densitometry and normalized to β-actin mRNA. The values shown are mean ± SEM of data from three independent experiments. # Significant compared with control alone, $p<0.05$. * Significant compared with LPS alone, $p<0.05$.
doi:10.1371/journal.pone.0021891.g002

Figure 3. Inhibitory effects of gastrodin on the LPS-induced expression of protein and mRNA for COX-2 in BV-2 cells. Approximately $1 \times 10^6$ cells/ml were seeded in six-well plates and incubated until 80% confluency. Cells were pre-treated with gastrodin (30, 40, and 60 μM) for 1 h, then exposed to 1 μg/ml LPS for 4 h. The levels of protein and the corresponding mRNA were determined by double-immunofluorescence labeling and RT-PCR as described in the Methods. Panel A shows the immunofluorescence images for protein expression of COX-2 and Panel B shows the corresponding mRNA data. The relative mRNA level was quantified by scanning densitometry and normalized to β-actin mRNA. The values shown are mean ± SEM of data from three independent experiments. # Significant compared with control alone, $p<0.05$. * Significant compared with LPS alone, $p<0.05$.
doi:10.1371/journal.pone.0021891.g003
expression levels of JNK and p38 MAPK in LPS-stimulated BV-2 cells (Figure 7D and 7E).

Discussion

Microglial activation has both beneficial and harmful effects on neuronal cell survival [28]. However, there are multiple lines of evidence suggesting that microglial activation is more associated with neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease [29,30]. Over-activation of microglia contributes to neurodegenerative processes through the production of various neurotoxic factors including free radicals and proinflammatory cytokines [31]. Therefore, inhibition of microglial activation may be a potential therapeutic strategy to reduce neuronal cell death. In fact, a number of anti-inflammatory agents, which inhibit microglial activation or production of proinflamm-
Figure 6. Inhibitory effects of gastrodin on the LPS-induced expression of protein and mRNA for NF-κB/RelA in BV-2 cells. Approximately 1 x 10^5 cells/ml were seeded in six-well plates and incubated until 80% confluency. Cells were pre-treated with gastrodin (30, 40, and 60 μM) for 1 h, then exposed to 1 μg/ml LPS for 4 h. The levels of protein and the corresponding mRNA were determined by double-immunofluorescence labeling and RT-PCR as described in the Methods. Panel A shows the immunofluorescence images for protein expression of NF-κB/RelA and Panel B shows the corresponding mRNA data. The relative mRNA level was quantified by scanning densitometry and normalized to β-actin mRNA. The values shown are mean ± SEM of data from three independent experiments. * Significant compared with control alone, p<0.05.

doi:10.1371/journal.pone.0021891.g006
MAPKs family has been shown to play important roles in LPS-induced iNOS, COX-2, and proinflammatory cytokines expression in many types of cells [46, 47, 48]. It also has been reported that LPS-induced expression of proinflammatory cytokines expression is mediated by MAPKs signal transduction pathway in BV-2 cells [34]. Therefore, we investigated the effect of gastrodin on activation (phosphorylation) of three MAPKs induced by LPS in BV-2 cells. In our study, LPS increased activation of MAPKs, including ERK1/2, JNK, and p38 MAPK, within 30 min after stimulation, whereas gastrodin decreased LPS-induced activation of MAPKs, which was accompanied by alterations in iNOS, COX-2, and proinflammatory cytokines. These results suggested that gastrodin-mediated attenuation of proinflammatory mediators is associated with down-regulation of the MAPK signaling pathway.

The present results have shown that gastrodin significantly suppressed LPS-upregulated expression levels of iNOS, COX-2,
IL-1β and NF-κB/RelA, though not TNF-α, in BV-2 cells in a dose-dependent manner; on the other hand, its inhibitory effects were not followed dose-dependently in the mRNA expression of these biomarkers. The same phenomenon was manifested by the inhibitory effects on phosphorylation of IκB-α, CREB, MAPKs including ERK1/2, JNK and p38 MAPK. Hence, while the inhibitory effects of gastrodin on the above-mentioned various cytokines and enzymes linked to various signaling routes are unequivocal, the actual mechanistic link between them remains to be fully elucidated. In view of the fact that gastrodin did not inhibit phosphorylation of IκB-α or the various signaling routes in a dose-dependent manner, the possibility that other pathways by which gastrodin can regulate the target proteins investigated should be considered. In addition, it needs to be pointed out that the inhibitory changes as observed in this study were based on a single time point. Considering the effects of LPS and gastrodin develop over a significant period of time, a time course study to investigate these time-related aspects would appear to be important.

In conclusion, we show here the inhibitory effects of gastrodin on LPS-induced proinflammatory mediators in microglial BV-2 cells. In this connection, gastrodin significantly attenuated the expression levels of neurotoxic proinflammatory mediators, including iNOS, COX-2, and proinflammatory cytokines (TNF-α and IL-1β) in LPS-stimulated microglial cells. This was accompanied by attenuation of expression levels of NF-κB/RelA protein and phosphorylation of IκB-α and CREB. Furthermore, levels of phosphorylated MAPKs, including ERK1/2, JNK, and p38 MAPK, were significantly decreased by pre-treatment with gastrodin in LPS-stimulated microglial cells. Taken together, these results indicate that gastrodin exerts its anti-inflammatory actions by inhibition of the NF-κB signaling pathway and phosphorylation of MAPKs. Arising from the above, we suggest that gastrodin is a potential an anti-inflammatory drug candidate in neurodegenerative diseases.

**Methods**

**Cells and treatments**

The immortalized mouse microglial cell line BV-2 was developed in the laboratory of Dr Blasi at the University of Perugia [49] and was a generous gift of Dr Cheng-gang Zou (School of Life Science, Yunnan University, Kunming, China). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco/BRL, Gaithersburg, MD, USA) containing 2% fetal bovine serum (HyClone, Logan, UT, USA) and antibiotics (100 IU/ml penicillin and 100 μg/ml streptomycin; Sigma, St. Louis, MO, USA) at a density not exceeding 5 × 10^5 cells/ml and maintained at 37°C in a humidified incubator with 5% CO₂. To harvest BV-2 cells, cells were trypsinized (0.25% trypsin/EDTA in phosphate-buffered saline (PBS); Sigma, St. Louis, MO, USA), then centrifuged (400 g for 10 min) and resuspended in serum-free DMEM. Cells were counted with a hemocytometer and trypsin blue staining (0.4% trypsin blue in PBS; Sigma) showed more than 99% of the cells retained viability. Cells (approximately 1 × 10⁶ cells/ml) were seeded in six-well plates before being subjected to treatments. Five groups of BV-2 cells were subjected to various treatments. In group 1, the cells were incubated in serum-free DMEM. In group 2, the cells were treated with 1 μg/ml LPS (from *Escherichia coli*, Sigma). In groups 3, 4, and 5, the cells were treated with 30 μM, 40 μM, and 60 μM gastrodin (Kunming Pharmaceutical Corporation, Kunming, China) for 1 h and then stimulated with LPS (1 μg/ml). This time point was chosen to minimize the possibility of any direct interactions between gastrodin and LPS. Cell incubations were for 30 min–4 h, as indicated in the text.

**Double-immunofluorescence labeling assay**

Various treated BV-2 cells were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (PB) for 15 min. After rinsing with PBS, the coverslips with adherent cells were used for double-immunofluorescence labeling assay. BV-2 cells were incubated with DAPI (dilution 1:50,000; Sigma) plus goat anti-mouse iNOS (dilution 1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA), goat anti-mouse COX-2 (dilution 1:500; Santa Cruz Biotechnology), goat anti-rabbit TNF-α polyclonal antibody (dilution 1:500; Chemicon, Temecula, CA, USA), goat anti-rabbit IL-1β (dilution 1:500; Chemicon), or goat anti-rabbit NF-κB/RelA (dilution 1:500; Santa Cruz Biotechnology). Subsequently, the cells were incubated with TRITC-conjugated secondary antibodies (Santa Cruz Biotechnology) for 1 h at room temperature. For negative controls, a set of culture slides was incubated under similar conditions without the primary antibodies. All images were captured with a fluorescence microscope (D80; Nikon, Tokyo, Japan). The results are representative of three independent experiments.

**Reverse transcription-polymerase chain reaction (RT-PCR) analysis**

Total RNA was prepared from BV-2 cells by using the Trizol® reagent (Invitrogen Corporation, Carlsbad, CA, USA) according to the manufacturer’s protocol. Total RNA was reverse-transcribed by using the Superscript™-III kit (Invitrogen) with 2.5 μg total RNA and oligo dT. Primer sequences were as follows: iNOS, sense: 5′- CTGCAAGCAGTTGGATGGAGAACCC TG -3′, antisense: 5′- GGAGATAGCCCGTGCTGACACCTGAA -3′; COX-2, sense: 5′-TTGAAGGCAAGGTAGTACAGC -3′, antisense: 5′- GGTAACATTCTAGAGATCG -3′; TNF-α, sense: 5′- CGTGAGGCGATTTTGTCTATCT -3′, antisense: 5′-CCAGCTCCGCAAA GTCTAAAG -3′; IL-1β, sense: 5′-GCCCATCTCTCTGT-GACTC -3′, antisense: 5′-AGGCCAC AGGTATTCTGT- CG -3′; NF-κB/RelA, sense: 5′-GGTGACACTTCTGGG-GAGT -3′, antisense: 5′-CCGAAAGGAGGCTATCACC -3′; β-actin, sense: 5′-AGGGGATGAAGTGAAGGACTCC -3′, antisense: 5′-GGTGTCGTGGTTGGAAGCTGTA -3′. PCR amplification of the resulting cDNA template was conducted by using the following conditions for 45 (TNF-α, IL-1β, NF-κB/RelA and β-actin), 36 (COX-2) or 27 (iNOS) cycles. After an initial denaturation step at 95°C for 15 min, temperature cycling was initiated. Each cycle consisted of denaturation at 94°C for 15 sec, annealing at 60°C for 25 sec, and elongation at 72°C for 30 sec (TNF-α, IL-1β, NF-κB/RelA and β-actin). After an initial denaturation step at 95°C for 5 min, temperature cycling was initiated. Each cycle consisted of denaturation at 94°C for 30 sec, annealing at 57°C for 45 sec, and elongation at 72°C for 30 sec (COX-2). After an initial denaturation step at 95°C for 5 min, temperature cycling was initiated. Each cycle consisted of denaturation at 94°C for 45 sec, annealing at 60°C for 45 sec, and elongation at 70°C for 1 min (iNOS). PCR products were analyzed on 1% agarose gels and stained with 1 mg/ml ethidium bromide. Images were captured with a Gel Doc 2000 image analyzer (Bio-Rad, Richmond, CA, USA). The results are representative of three independent experiments.

**Western blot analysis**

BV-2 cells were plated overnight in 6 well plates at a density of 5 × 10⁵ cells per plate, then the cells were further incubated in the
medium without 10% FBS for at least 4 h before treatments. Cells were harvested with ice-cold PBS and centrifuged at 16,000 g for 5 min at 4°C. Stimulated cells were lysed in ice-cold lysis buffer [62.5 mM Tris–HCl, pH 8.8, 250 mM glycerol, 2% sodium dodecyl sulphate (SDS), 0.01% bromophenol blue and 5% β-mercaptoethanol]. Cell lysates were centrifuged at 16,000 g for 5 min at 4°C, then the supernatants were collected. Protein content was determined by using the BCA protein assay (Pierce, Rockford, IL, USA). Equal amounts of protein (50 µg were loaded per lane onto 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto immunoblot polyvinylidene difluoride membranes (Chemicon). The membranes were blocked with 5% non-fat milk in Tris-buffered saline containing 0.1% Tween 20 (TBS-T) for 2 h at room temperature and incubated separately with goat anti-rabbit antibodies for ERK1/2 and phospho-ERK1/2, JNK and phospho-JNK, p38 MAPK and phospho-p38 MAPK, phospho-IκB-α, phospho-CREB and β-actin antibodies (1:1000 dilution; Cell Signaling Technology, Danvers, MA, USA) that recognize different molecules under study for overnight at 4°C. The membranes were then washed three times for 15 min with TBS-T, and incubated with a 1:2000 dilution of horseradish peroxidase-coupled secondary antibodies (Santa Cruz Biotechnology). Membranes were incubated with TBS-T, and incubated with a 1:2000 dilution of horseradish peroxidase-coupled secondary antibodies (Santa Cruz Biotechnology) for 2 h at room temperature. Blots were again washed three times for 5 min each in TBS-T and developed by the ECL® detection system (Santa Cruz Biotechnology). Membranes were exposed to Fuji Medical X-Ray Film (Fuji Photo Film Co., Ltd, Karagawa, Japan). The results are representative of three independent experiments.

Statistical analysis

Statistical analysis of the data was carried out by one way analysis of variance (ANOVA) followed by Scheffe’s post hoc test, using SPSS (SPSS Inc., Chicago, IL, USA). Summary data are shown as mean ± SEM (standard error of mean) obtained from three independent experiments. Values of p<0.05 were considered significant.

Author Contributions

Conceived and designed the experiments: JS DL. Performed the experiments: J-ND YZ L-MZ WZ. Analyzed the data: Y-ML J-ND JS L-GB. Contributed reagents/materials/analysis tools: YZ Q-LA Y-DL Y-ML. Wrote the paper: DL J-ND.

References

1. Olson JK, Miller SD (2004) Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 173: 3916–3924.
2. Nakajima K, Kohsaka S (1996) Functional roles of microglia in the central nervous system. Hum Cell 11: 141–153.
3. Suzumura A, Takeuchi H, Zhang G, Kuno R, Mizuno T (2006) Roles of gliadervived cytokines on neuronal degeneration and regeneration. Ann N Y Acad Sci 1088: 219–229.
4. Roy A, Fung YK, Liu X, Pahan K (2006) Up-regulation of Microglial CD11b expression by NO. J Biol Chem 281: 14971–14980.
5. Arney DP, Popovich PG (2009) Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury. Neuroscience 158: 1112–1121.
6. Fontana A, Gast H, Reith W, Recher M, Birchler T, et al. (2010) Naloxepine: autoimmunity, tumor cell TCR activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? Brain 133: 1300–1311.
7. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, et al. (2007) Imaging microglial activation in Huntington’s disease. Brain Res Bull 72: 148–151.
8. Weiner HL (2009) The challenge of multiple sclerosis: how do we cure a chronic neurodegenerative disease? J Mol Neurosci 33: 94–99.
9. Amor S, Puentes F, Baker D, van der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology 129: 154–169.
10. Nam KN, Koketsu M, Lee EH (2008) 5-Chloroacetyl-2-amino-1,3-selenazoles inhibit TNF-α-induced JNK and MLK3/JNK signaling cascades. J Neuroinflammation 7: 99–116.
11. Choi Y, Lee MK, Lim SY, Sung SH, Kim YC (2009) Inhibition of inducible NO synthase, cyclooxygenase-2 and interleukin-1β by toridin is mediated by nitrogens-activated protein kinase in microglial BV2 cells. Br J Pharmacol 156: 933–940.
12. Cao Q, Li P, Lu J, Dhen ST, Kaur C, et al. (2010) Nuclear factor-kappaB/p65 responds to changes in the Notch signaling pathway in murine BV-2 cells and in amesloid microglia in postnatal rats treated with the gamma-secretase complex blocker DAPT. J Neurosci Res 88: 2701–2714.
13. Murphy S (2000) Production of nitric oxide by glial cells: regulation and potential roles in the CNS. Glia 29: 1–13.
14. Bal-Price A, Matthias A, Brown GC (2002) Stimulation of the NADPH oxidase in activated rat microglia removes nitric oxide but induces peroxynitrite production. J Neurochem 80: 73–80.
15. Wang JY, Shum AY, Ho YJ, Wang JY (2003) Oxidative neurotoxicity in rat cerebral cortex neurons: synergistic effects of H2O2 and NO on apoptosis involving activation of p38 mitogen-activated protein kinase and caspase-3. J Neurosci Res 72: 508–519.
16. Salveni C, Misko TP, Masferrer JL, Seibert K, Currie MG, et al. (1993) Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 90: 7240–7244.
17. Liang X, Wu L, Wang Q, Hand T, Blak M, et al. (2007) Function of COX-2 and prostaglandins in neurodegenerative disease. J Mol Neurosci 33: 94–99.
18. Brown GG, Neher JJ (2010) Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 41: 242–247.
19. Martindale JL, Holbrook NJ (2002) Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 192: 1–15.
20. Ajmone-Cat MA, De Simone R, Nicolini A, Mingheri L, Martini A (2003) Effects of N-acetylcysteine on p38 mitogen activated protein kinase, cyclic AMP, responding element binding protein and nuclear factor-kappaB activation in resting and activated microglial cells. J Neurochem 84: 413–416.
21. Ojermann LM, Nelson WL, Shin DS, Rowe AO, Buchanan RA (2006) Tian man, an ancient Chinese herb, offers new options for the treatment of epilepsy and other conditions. Epilepsy Behav 8: 376–383.
22. Liu LC, Chen YF, Lee WC, Wu YT, Tsai TH (2008) Pharmacokinetics of gastrodin and its metabolite p-hydroxybenzyl alcohol in rat blood, brain and bile by microdialysis coupled to LC/MS/MS. J Pharm Biomed Anal 48: 909–917.
23. Zeng X, Zhang S, Zhang L, Zhang K, Zheng X (2006) A study of the neuroprotective effect of the phenolic glucoside gastrodin during cerebral ischemia in vivo and in vitro. Planta Med 72: 1359–1365.
24. Xu X, Lu Y, Bie X (2007) Protective effects of gastrodin on hypoxia-induced toxicity in primary cultures of rat cortical neurons. Planta Med 73: 650–654.
25. Haich MT, Wu CR, Chen CF (1997) Gastrodin and p-hydroxybenzyl alcohol facilitate memory consolidation and retrieval, but not acquisition, on the passive avoidance task in rats. J Ethnopharmacol 56: 43–54.
26. Wu CR, Haich MT, Huang SC, Peng WH, Chang YS, et al. (1996) Effects of Gastrodia elata and its active constituents on scopoline-induced amnesia in rats. Planta Med 62: 317–321.
27. Nakajima K, Kohsaka S (2001) Microglia: activation and their significance in the central nervous system. J Biochem 130: 169–175.
28. Long-Smith CM, Sullivan AM, Nolan YM (2009) The influence of microglia on the pathogenesis of Parkinson’s disease. Prog Neurobiol 89: 277–287.
29. Lu LF, Kuo YM, Beach T, Walker DG (2010) Microglia activation and anti-inflammatory regulation in Alzheimer’s disease. Mol Neurobiol 41: 115–128.
30. Kiegeris A, McGeer EG, McGeer PL (2007) Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol 20: 351–357.
31. Asamuma M, Miyazaki I, Ogawa N (2004) Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative disease. Curr Pharm Des 10: 695–700.
32. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37: 510–518.
33. Lim JY, Won TJ, Hwang BY, Kim HR, Hwang KW, et al. (2010) The new diterpene isodojaponin D inhibited LPS-induced microglial activation through NF-kappaB and MAPK signaling pathways. Eur J Pharmacol 642: 10–18.
34. Giovannini MG, Scali C, Prosperi G, Bellucci A, Pepeu G, et al. (2003) Experimental brain inflammation and neurodegeneration as model of Alzheimer’s disease: protective effects of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 16: 31–40.
35. Miller RJ, James-Krake M, Sun NY, AW (2009) Oxidative and inflammatory pathways in Parkinson’s disease. Neurochem Res 34: 55–65.
36. Hanisch UK (2002) Microglia as a source and target of cytokines. Glia 40: 140–155.
38. Son HY, Han HS, Jung HW, Park YK (2009) Panax notoginseng attenuates the infarct volume in rat ischemic brain and the inflammatory response of microglia. J Pharmacol Sci 109: 368–379.
39. Lee MJ, Yang CH, Jeon JP, Hwang M (2009) Protective effects of isoliquiritigenin against methamphetamine-induced neurotoxicity in mice. J Pharmacol Sci 111: 216–220.
40. Nam KN, Park YM, Jung HJ, Lee JY, Min BD, et al. (2010) Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol 648: 110–116.
41. Szczepanik AM, Ringheim GE (2003) IL-10 and glucocorticoids inhibit Abeta(1–42)- and lipopolysaccharide-induced pro-inflammatory cytokine and chemokine induction in the central nervous system. J Alzheimers Dis 5: 105–117.
42. Vaillancourt F, Morquette B, Shi Q, Fahmi H, Lavigne P, et al. (2007) Differential regulation of cyclooxygenase-2 and inducible nitric oxide synthase by 4-hydroxynonenal in human osteoarthritic chondrocytes through ATF-2/CREB-1 transactivation and concomitant inhibition of NF-kappaB signaling cascade. J Cell Biochem 100: 1217–1231.
43. Yabe T, Sanagi T, Schwartz JP, Yamada H (2005) Pigment epithelium-derived factor induces pro-inflammatory genes in neonatal astrocytes through activation of NF-kappa B and CREB. Glia 50: 223–234.
44. Vitor CE, Figueiredo CP, Hara DB, Bento AF, Mazzuco TL, et al. (2009) Therapeutic action and underlying mechanisms of a combination of two pentacyclic triterpenes, alpha- and beta-amyrin, in a mouse model of colitis. Br J Pharmacol 157: 1034–1044.
45. Spooren A, Krooijman R, Linthemas B, Van Craenenbroeck K, Vermeulen L, et al. (2010) Cooperation of NF-kappaB and CREB to induce synergistic IL-6 expression in astrocytes. Cell Signal 22: 871–881.
46. Matsuda T, Omori K, Vuong T, Pascual M, Valiente L, et al. (2005) Inhibition of p38 pathway suppresses human islet production of pro-inflammatory cytokines and improves islet graft function. Am J Transplant 5: 484–493.
47. Hatziieremia S, Gray AI, Ferro VA, Paul A, Plevin R (2006) The effects of cardamonin on lipopolysaccharide-induced inflammatory protein production and MAP kinase and NF-kappaB signaling pathways in monocytes/macrophages. Br J Pharmacol 149: 188–198.
48. Chen SR, Xu XZ, Wang YH, Chen JW, Xu SW, et al. (2010) Icaritin derivative inhibits inflammation through suppression of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways. Biol Pharm Bull 33: 1307–1315.
49. Blasi E, Baruzzi R, Bocchini V, Mazzaola R, Bistoni F (1996) Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol 27: 229–237.